Organon & Co. (NYSE:OGN) Q2 2024 Earnings Call Transcript August 6, 2024 8:30 AM ET Company Participants Jennifer Halchak - Head of IR Kevin Ali - CEO Matt Walsh - CFO Conference Call Participants Umer Raffat - Evercore ISI Ethan Brown - JPMorgan David Amsellem - Piper Sandler Jason Gerberry - Bank of America Terence Flynn - Morgan Stanley Chris Shibutani - Goldman Sachs Operator Thank you for standing-by. My name is Mandeep, and I'll be your operator today. At this time, I'd like to welcome everyone to the ...

Organon (OGN) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 5.66%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.97 per share when it actually produced earnings of $1.22, delivering a surprise of 25.77%. Over the last four quarters, the co ...

业绩总结 - 2024年第二季度公司的收入为16亿美元，同比增长2%[6] - 调整后的EBITDA为5.13亿美元，同比下降3%[15] - 调整后的稀释每股收益为1.12美元，同比下降15%[15] - 2024年迄今收入为32.29亿美元，同比增长3%[15] - 2024年第二季度调整后的毛利为9.96亿美元，同比下降2%[15] - 2024年第二季度GAAP稀释每股收益为0.75美元，同比下降21.1%[27] - 2024年迄今GAAP净收入为396百万美元，同比下降5.5%[27] 用户数据 - 女性健康业务的收入为4.49亿美元，同比增长3%[11] - 生物仿制药业务的收入为1.64亿美元，同比增长22%[12] - 已建立品牌的收入为9.63亿美元，同比下降3%[13] - 在美国市场，收入为3.88亿美元，同比增长5%[8] - 欧洲和加拿大市场的收入为4.57亿美元，同比下降2%[8] - 拉丁美洲、中东、俄罗斯和非洲市场的收入为2.51亿美元，同比增长7%[8] - 约75%的年初至今销售额来自美国以外的市场[9] 未来展望 - 预计2024年自由现金流在扣除一次性分拆相关费用前将达到约10亿美元[16] - 2024年预计将是连续第三年在固定汇率下实现收入增长，收入范围调整为62.5亿至64.5亿美元[20] - 2024年6月的净杠杆比率约为4.1倍，预计2024年底将低于4.0倍[17] 新产品和新技术研发 - 2024年第二季度研发费用为1.10亿美元，同比下降9%[25] - 2024年迄今研发费用为2.16亿美元，同比下降11%[25] - 公司在女性健康领域拥有14种产品，在生物仿制药领域拥有5种产品，在成熟品牌领域拥有55种产品[29] 其他新策略和有价值的信息 - 2024年第二季度的非GAAP调整影响总额为0.37美元，较2023年第二季度的0.36美元略有上升[27] - 2024年第二季度的利息支出为131百万美元，同比下降0.8%[27] - 2024年第二季度的税收支出为40百万美元，同比上升233.3%[27] - 2024年第二季度的折旧费用为31百万美元，同比上升10.7%[27]

财务业绩 - 公司第二季度2024年收入16.07亿美元，同比持平，剔除汇率影响后增长2%[2][3][8] - 第二季度2024年稀释每股收益0.75美元，非GAAP调整后每股收益1.12美元，其中包括1500万美元的研发费用[3] - 第二季度2024年净利润1.95亿美元，调整后EBITDA5.13亿美元[3] - 全年2024年收入指引6.25亿美元至6.45亿美元，调整后EBITDA利润率指引31%-33%[4] - 2024年第二季度和上半年收入分别为16.07亿美元和32.29亿美元[36] - 2024年第二季度和上半年毛利分别为9.39亿美元和18.96亿美元[36] - 2024年第二季度和上半年净利润分别为1.95亿美元和3.96亿美元[37] - 2024年第二季度和上半年每股收益(稀释)分别为0.75美元和1.53美元[38] - 公司第二季度收入为16.07亿美元，与去年同期持平[45] - 公司第二季度毛利率为62.0%，较去年同期下降0.9个百分点[49] - 公司第二季度销售、一般及管理费用为3.90亿美元，与去年同期持平[50] - 公司第二季度研发费用为1.10亿美元，较去年同期下降9.1%[52] - 公司第二季度非GAAP调整后净利润为2.89亿美元，较去年同期下降14.0%[53] - 公司第二季度非GAAP调整后每股收益为1.12美元，较去年同期下降14.5%[55] - 公司第二季度非GAAP调整后EBITDA为5.13亿美元，较去年同期下降3.2%[56] - 公司第二季度非GAAP调整后EBITDA利润率为31.9%，较去年同期下降1.1个百分点[56] - 公司第二季度税率为17.8%，较去年同期上升8.4个百分点[54] - 公司第二季度拆分相关成本为3900万美元，较去年同期下降36.1%[57] 业务表现 - 妇女健康业务收入增长3%，主要由于Nexplanon销售强劲[9] - 生物类似药业务收入增长22%，主要由于Hadlima上市后销售增长[11] - 成熟品牌业务收入下降1%，主要受中国带量采购和日本价格调整的影响[12] - Nexplanon/Implanon NXT在2024年第二季度和上半年的销售额分别为2.42亿美元和4.62亿美元[42] - Renflexis在2024年第二季度和上半年的销售额分别为0.69亿美元和1.38亿美元[42] - Zetia在2024年第二季度和上半年的销售额分别为0.75亿美元和1.59亿美元[42] - Atozet在2024年第二季度和上半年的销售额分别为1.40亿美元和2.71亿美元[42] - Singulair在2024年第二季度和上半年的销售额分别为0.93亿美元和1.90亿美元[42] 其他 - 董事会宣布每股0.28美元的季度股息[20] - 第二季度毛利率58.4%，调整后毛利率62%，主要受产品组合不利影响[17]

Organon & Co. (OGN) is scheduled to report second-quarter 2024 results on Aug 6, before market open. In the last reported quarter, the company's adjusted earnings per share (EPS) of $1.22 surpassed the Zacks Consensus Estimate by 25.8%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on three occasions and missed once, delivering an earnings surprise of 13.6%, on average. Let's check out the factors that have shaped OGN's performance prior to this announcement. Factor ...

Wall Street analysts expect Organon (OGN) to post quarterly earnings of $1.06 per share in its upcoming report, which indicates a year-over-year decline of 19.1%. Revenues are expected to be $1.63 billion, up 1.1% from the year-ago quarter. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 2.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period. Before a company announces its earni ...

The latest trading session saw Organon (OGN) ending at $21.86, denoting a -1.84% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 1.08% for the day. Elsewhere, the Dow saw an upswing of 0.75%, while the tech-heavy Nasdaq appreciated by 2.64%. Shares of the pharmaceutical company witnessed a gain of 10.69% over the previous month, beating the performance of the Medical sector with its gain of 0.71% and the S&P 500's loss of 0.44%. Analysts and investors al ...

Organon (OGN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 6. On the o ...

Lucy Lambriex/DigitalVision via Getty Images Investment Overview I last covered Organon (NYSE:OGN), a company whose stock I own, back in mid-February, reviewing a positive set of full-year 2023 earnings that sent shares rising in value from ~$16, to ~$19, adding fresh momentum to a bull run that began in December 2023. Until late-December, Organon stock had experienced a torrid 2023, sinking in value from $32 per share in January, to ~$11.5 at the end of November, for an overall loss of nearly 65%. The ...

Organon (OGN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of ...